Sienna's long-serving CEO steps down
Sienna Cancer Diagnostics has announced the resignation of CEO Dr Kerry Hegarty after 10 years at the helm.
The company has commenced a global search for a replacement, and Hegarty plans to stay on in a support capacity until a new chief is found.
Sienna Chairman Dr Geoff Cumming said Hegarty’s resignation serves as part of a long-term strategic transformation plan for the company.
“Over the past 12 months, Kerry and the board have been assessing the needs of the company as it embarks on its next chapter, including leadership and management needs for the next 2-3 years,” he said.
“As part of this process, the board and Kerry have agreed that now is an opportune time to attract a new and outstanding CEO to a transformed Sienna to lead the company into a new phase in its history, and allow Kerry to pursue other opportunities after many years of service.”
The move comes the same month Sienna secured its first revenue-generating deal for its telomerase detection technology based on Anti-hTERT antibody SCD-A7.
The company also recently completed a $2.1 million capital raising to help fund SCD-A7 development.
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
A pre-emptive approach to treating leukaemia relapse
The monitoring of measurable residual disease (MRD), medication and low-dose chemotherapy is...
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
